Nucleotide analogue prodrug and the preparation thereof
The present invention provides: 1) Derivative solid form of 9-[2-(R)-[bis[pivaloyloxymethoxy]-phosphinylmethoxy]propyl]adenine (bis-POM PMPA, abbreviated as TD hereinafter), including crystalline form A and form B of TD, TD fumarate salts and cyclodextrin inclusion complex of TD; 2) Synthesis and purification methods of TD and Solidification method of TD oil, including converting TD oil to crystalline TD in Form A and Form B, solid TD salts and cyclodextrin inclusion complex of TD; 3) Stable pharmaceutical compositions containing TD derivatives and their preparation; 4) The use of the above TD derivatives in the antiviral treatments, especially in the treatment of HIV, HBV, CMV, HSV-1, HSV-2 and human Herpes virus infections.
1. A derivative form of 9-[2-(R)-[bis[pivaloyloxymethoxy]-phosphinylmethoxy]propyl]adenine comprising a fumarate salt for treating hepatitis B infection of formula (III):
wherein the fumarate salt is a crystalline form having a XRD pattern expressed in terms of lattice spacing d usually comprising peaks at 18.706 Å, 4.562 Å, 3.561 Å, 3.033 Å, and 2.596 Å.
2. A pharmaceutical composition comprising an effective amount of the derivative form of claim 1 and a pharmaceutically acceptable carrier.
3. The derivative form of claim 1 , wherein the fumarate salt crystalline form having a XRD pattern expressed in terms of lattice spacing d further comprising peaks at 5.075 Å, 4.414 Å, 4.141 Å, 4.044 Å, 3.776 Å, 3.257 Å, 2.985 Å.
4. The pharmaceutical composition of claim 2 , further comprising L-carnitine or salt thereof.